Discover the Latest Innovations with SIBIONICS

Shenzhen Hosts the 2nd AGP&DTx Summit Forum: Advancing Digital Therapeutics in Diabetes Management

 

On July 5, the 2nd Ambulatory Glucose Profile (AGP) & Digital Therapeutics (DTx) Summit Forum(“Summit Forum”), led by the National Innovation Center for Advanced Medical Devices, sponsored by China AGP and DTx R&D Center ("R&D Center"), co-sponsored by Shenzhen SIBIONICS Technology Co., Ltd. ("SIBIONICS"), took place in Shenzhen, China. Domestic and overseas healthcare experts converged at the Summit Forum to explore the application of AGP in precision diagnosis and treatment of diabetes, and digital therapeutics during the decision-making process of clinical practice worldwide.

 

The Summit Forum was hosted by Professor Ji Linong, the initiator of China AGP&DTx R&D Center and clinical professor of Peking University People's Hospital, featuring leading endocrinology experts from Slovenia, Australia, Saudi Arabia, Serbia, Turkey, Algeria, and beyond. Experts delved into key topics such as AGP consensus, the database of Chinese diabetes patients, the artificial pancreas system, and digital health management. They also discussed the latest technological advancements in diabetes management and their practical applications in clinical practice.

 

At the conference, Professor Andrej Janež, the Head of the Department of Endocrinology at the Ljubljana University Medical Centre in Slovenia, highlighted China's advancements in AGP clinical practice. He remarked, “They’ve developed an AGP training program, and they're moving into the area of researching and using AI to enhance diagnosis and guide treatment decisions, leading to better diabetes care and facilitating AGP applications.”

 

To integrate global resources and drive innovation in diabetes diagnosis and treatment, the International Consortium for AGP&DTx R&D was founded at this forum. This initiative aims to standardize AGP clinical applications globally and provide a platform for international collaboration and knowledge sharing to elevate diabetes diagnosis and treatment worldwide.

 

About SIBIONICS

Founded in 2015, SIBIONICS is committed to the R&D and industrialization of implantable medical devices. By merging cutting-edge CGM technology with designs centered around diabetes patients, SIBIONICS strives to push the boundaries of what's possible in personalized diabetes management solutions. With over 1,000,000 users globally, SIBIONICS is now a beacon of reliability and innovation in diabetes management.

SIBIONICS Announced to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes(ATTD)

The company will be hosting an influencer meeting during the conference

SIBIONICS, the world’s third-largest Continuous Glucose Monitoring (CGM) System brand, announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on 6-9 March 2024. The company will showcase its latest CGM solutions for diabetes management at Booth No.15 at the conference. According to SIBIONICS, it has collaborated with over 1,800 hospitals on integrating their CGM for inpatient treatment, benefiting over 850,000 individuals worldwide in managing diabetes. Meanwhile, SIBIONICS is constructing an automated production line with an annual capacity of 18 million CGM sets, expected to be completed within 2024.
Having received CE MDR certification in October 2023, SIBIONICS CGM entered the European market in November. With strong product capabilities and positive user feedback, SIBIONICS quickly expanded global partnerships. In 2024, driven by the company's commitment to customer-centric innovation, SIBIONICS is dedicated to engaging with users for a co-developed CGM solution that precisely aligns with their needs. The commitment extends beyond Type 1 diabetes, focusing on Type 2 diabetes, prediabetes, and metabolic disorders. Emphasizing blood glucose management's importance, SIBIONICS aims to deliver comprehensive, high-quality diabetes solutions for overall health improvement.
During the ATTD conference, the company will be hosting an exhilarating brand event - SIBIONICS Influencer Talk: Realizing the Unimagined on March 9, 2024, where healthcare professionals, dietitians, and opinion leaders in the field of diabetes management will gather to delve into and discuss the extensive potential of CGM technology and its pivotal role in crafting future diabetes management solutions.
The “SIBIONICS Influencer Talk: Realizing the Unimagined” event will feature captivating discussions on the company’s upcoming launch plans for the new versions of the GS1 CGM - GS2, reusable transmitter GS ECO, and the combined glucose and ketone monitor (CGM/CKM), thought-provoking presentations, and interactive Q&A sessions, creating a vibrant atmosphere conducive to user co-developed diabetes management solutions.
This exciting and meaningful event is about to take place at the Hilton Garden Inn Florence Novoli in Florence, Italy on March 9, 2024. The company extends gratitude in advance to all the speakers, and brand partners who will be attending this event. SIBIONICS looks forward to continuing the conversation and pushing the boundaries of CGM innovation in its future events.
If the event piques your curiosity, feel free to contact the SIBIONICS PR Team at: zy.zhang@sibionics.com

SIBIONICS Made a Remarkable Presence at MEDICA 2023, Paving the Way for a New Future in Digital Diabetes Management

Düsseldorf, Germany - Last week, the highly acclaimed MEDICA 2023, took place successfully in Dusseldorf, Germany. The event attracted over 6,200 international companies, showcasing over 22,000 types of healthcare products and exchanging insights on cutting-edge medical technologies. By presenting its outstanding flagship continuous glucose monitoring(CGM) product, SIBIONICS effectively demonstrated its innovative accomplishments and technological prowess in the field of diabetes management on a global scale.


This exhibition coincidentally aligned with the significant occasion of the 17th World Diabetes Day, and this year's theme is “Know Your Risk, Know Your Response”. In a world where diabetes is increasingly prevalent, the emphasis on raising awareness about the risks becomes paramount. This theme underscores the importance of educating oneself of the risk factors associated with diabetes and being equipped with the knowledge to effectively respond to them. According to the International Diabetes Federation(IDF), 537 million adults worldwide - that’s 10% of the world’s adults were living with diabetes as of 2021. This number is predicted to rise to 643 million by 2030 and 783 million by 2045, posing an even greater public health challenge.

 

Amidst this challenge, SIBIONICS has brought its state-of-the-art GS1 CGM system at the prestigious MEDICA 2023, setting a new standard for diabetes management.
This groundbreaking solution meticulously monitors glucose levels with exceptional precision, dynamically adjusting to an individual's blood sugar fluctuations. It offers a personalized and proactive approach to diabetes management.

 

Launched in November 2021, the GS1 was the world’s second CGM that applies the working principle of second-generation glucose sensors. This calibration-free, non-scanning and easy-to-use CGM provides up to 14 days of continuous glucose monitoring. To further assist users in better diabetes management, the GS1 CGM also facilitates data sharing with friends and family while seamlessly integrating the latest ProView remote access platform. This equips healthcare providers with the ability to monitor remotely and deliver timely medical interventions as needed.


SIBIONICS has pioneered an integrated technological system grounded in the principles of second-generation sensors. This system has not only attained a sensor process design characterized by high throughput, high consistency, and high stability but also accomplished the independent synthesis of all raw materials, ranging from electrodes and enzyme polymers to semi-permeable membranes. This establishes the foundation for the SIBIONICS CGM system’s global competitiveness, making it a noteworthy highlight at the MEDICA conference. The GS1 CGM has obtained the EU MDR certification, qualifying it for entry into the European market. It is also noted that numerous international distributors have shown interest in partnering with SIBIONICS, foreseeing collaborative efforts in exploring the European market. This advancement is poised to yield positive outcomes for individuals affected by diabetes in Europe.

 

"The remarkable presence of SIBIONICS at MEDICA 2023 marks a significant milestone in the global landscape of diabetes management," said Nowlin Patrick Stewart, Chief Strategy Officer, “And we are proud to showcase the technological advancements and capabilities that SIBIONICS brings to the forefront of medical device manufacturing." 

 

About SIBIONICS:

Established in 2015, SIBIONICS is a dynamic and innovative medical technology company dedicated to developing advanced solutions for individuals with diabetes. Their mission is to empower diabetes management worldwide, through a combination of implantable medical hardware and a suite of artificial intelligence algorithms while prioritizing CGM accuracy and user-centric design.

SIBIONICS Achieves Milestone: Receiving CE Mark for Its Groundbreaking GS1 CGM

SIBIONICS, the third biggest CGM brand worldwide, is delighted to announce that it has received the CE Mark for its revolutionary GS1 Continuous Glucose Monitoring System (CGM). This significant milestone marks a momentous achievement for SIBIONICS and paves the way for the distribution and utilization of this game-changing technology throughout the European market.

The CE Mark, also known as the "Conformité Européene" or European Conformity, is a certification indicating that a product complies with European Union (EU) health and safety requirements, demonstrating the quality, safety, and efficacy of the product.

Established in 2015, SIBIONICS boasts a workforce exceeding 700 individuals, with over 40% actively engaged in research and development efforts. As of today, SIBIONICS has collaborated with 1,600 hospitals on adopting the GS1 CGM for inpatient treatment and over 600,000 users have been managing their diabetes with GS1 globally. With production capacity of 6,000,000 units per year and each batch consistently achieving a low MARD value of 8.83%, SIBIONICS is confident to serve a larger customer base.

At its core, the SIBIONICS GS1 CGM System is designed to empower both healthcare professionals and patients with the information they need to make informed treatment decisions and maintain optimal glucose control.

The SIBIONICS GS1 CGM offers users calibration-free, 14 days of continuous glucose monitoring, with the ability to transmit glucose data to their monitoring devices or mobile applications, and generate professional AGP reports. To aid users in better diabetes management, GS1 CGM not only supports data sharing with friends and family but also integrates the latest ProView remote access platform. This platform allows healthcare providers to remotely monitor and provide timely medical interventions.

As an innovative MedTech company that combines medical technology with artificial intelligence, SIBIONICS will strive to bring their innovative and groundbreaking diabetes management technology and expertise to more diabetes patients across the globe.

Simultaneously, SIBIONICS is vigorously expanding its presence in various specialized segments within the area of health management. Their successful launch of the consumer-grade biowearable - the KS1 Continuous Ketone Monitoring System(CKM), has garnered enthusiastic acclaim from consumers.Those interested can find more information here: www.sibiosensor.com

30 October, 2023

SIBIONICS Made an Impressive Debut @ EASD 2023

SIBIONICS made an impressive debut at EASD 2023, showcasing our flagship product, the SIBIONICS GS1 CGM system.

Looking back at the entire exhibition, our professional team focused on products & services and had pleasant and in-depth discussions with customers. At the same time, we had extensive conversations with industry experts and discussed in depth the future development and application of CGM in diabetes care. SIBIONICS was recognised by many industry experts at the exhibition and raised expectations for the future of our brand.

The exhibition ended successfully, with significant progress made and support and attention from all parties. We would like to thank everyone who visited our stand; your participation enriched the event and gave it meaning.

As we look to the future, we expect SIBIONICS to continue to move forward, and our goal is to help people with diabetes better manage their lives and create more glorious moments in the future.

2-6 October, 2023